FDA Obtains Permanent Injunction Barring Neilgen Pharmaceuticals Inc. and Advent Pharmaceuticals, Inc. from Manufacturing and Distributing Unapproved Drugs
FDA -- The U.S. Food and Drug Administration today announced that it had obtained a permanent injunction barring Neilgen Pharmaceuticals Inc. of Westminster, Md., its parent company, Advent Pharmaceuticals, Inc. (Advent), of East Windsor, N.J., and two of their officers, Bharat Patel and Pragna Patel, from manufacturing and distributing any unapproved, adulterated or misbranded drugs.